The pharma industry has been making great strides forward in digital health, but one element of that – gamification – hasn’t yet made much headway in the sector.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh